Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations

Authors: Rosario Menéndez, Raúl Méndez, Eva Polverino, Edmundo Rosales-Mayor, Isabel Amara-Elori, Soledad Reyes, José Miguel Sahuquillo-Arce, Laia Fernández-Barat, Victoria Alcaraz, Antoni Torres

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Non-cystic fibrosis bronchiectasis is a chronic structural lung condition that courses with recurrent infectious exacerbations that lead to frequent antibiotic treatment making this population more susceptible to acquire pathogens with antibiotic resistance. We aimed to investigate risk factors associated with isolation of multidrug-resistant pathogens in bronchiectasis exacerbations.

Methods

A prospective observational study was conducted in two tertiary-care hospitals, enrolling patients when first exacerbation appeared. Multidrug-resistance was determined according to European Centre of Diseases Prevention and Control classification.

Results

Two hundred thirty three exacerbations were included and microorganisms were isolated in 159 episodes. Multidrug-resistant pathogens were found in 20.1% episodes: Pseudomonas aeruginosa (48.5%), methicillin-resistant Staphylococcus aureus (18.2%) and Extended spectrum betalactamase + Enterobacteriaceae (6.1%), and they were more frequent in exacerbations requiring hospitalization (24.5% vs. 10.2%, p: 0.016). Three independent multidrug-resistant risk factors were found: chronic renal disease (Odds ratio (OR), 7.60, 95% CI 1.92–30.09), hospitalization in the previous year (OR, 3.88 95% CI 1.37–11.02) and prior multidrug-resistant isolation (OR, 5.58, 95% CI 2.02–15.46). The proportion of multidrug-resistant in the 233 exacerbations was as follows: 3.9% in patients without risk factors, 12.6% in those with 1 factor and 53.6% if ≥2 risk factors.

Conclusions

Hospitalization in the previous year, chronic renal disease, and prior multidrug-resistant isolation are risk factors for identification multidrug-resistant pathogens in exacerbations. This information may assist clinicians in choosing empirical antibiotics in daily clinical practice.
Literature
3.
go back to reference Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P, et al. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax [Internet]. 2013 [cited 2014 Jan 5];68:997–999. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23774884. Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P, et al. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax [Internet]. 2013 [cited 2014 Jan 5];68:997–999. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23774884.
4.
go back to reference Prina E, Ranzani OT, Polverino E, Cillóniz C, Ferrer M, Fernandez L, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. [Internet]. 2015 [cited 2015 Dec 3];12:153–160. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25521229. Prina E, Ranzani OT, Polverino E, Cillóniz C, Ferrer M, Fernandez L, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. [Internet]. 2015 [cited 2015 Dec 3];12:153–160. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25521229.
5.
go back to reference Vendrell M, de Gracia J, Olveira C, Martínez MA, Girón R, Máiz L, et al. [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery]. Arch Bronconeumol. [Internet]. 2008 [cited 2015 Dec 30];44:629–640. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19007570. Vendrell M, de Gracia J, Olveira C, Martínez MA, Girón R, Máiz L, et al. [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery]. Arch Bronconeumol. [Internet]. 2008 [cited 2015 Dec 30];44:629–640. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​19007570.
8.
go back to reference Martínez-García MÁ, de Gracia J, Vendrell Relat M, Girón R-M, Máiz Carro L, de la Rosa Carrillo D, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J [Internet]. 2014 [cited 2015 Dec 28];43:1357–1367. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24232697. Martínez-García MÁ, de Gracia J, Vendrell Relat M, Girón R-M, Máiz Carro L, de la Rosa Carrillo D, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J [Internet]. 2014 [cited 2015 Dec 28];43:1357–1367. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​24232697.
9.
go back to reference Polverino E, Cilloniz C, Menendez R, Gabarrus A, Rosales-Mayor E, Alcaraz V, et al. Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients. J Infect. [Internet]. 2015 [cited 2015 Dec 30];71:28–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25882347. Polverino E, Cilloniz C, Menendez R, Gabarrus A, Rosales-Mayor E, Alcaraz V, et al. Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients. J Infect. [Internet]. 2015 [cited 2015 Dec 30];71:28–36. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25882347.
10.
go back to reference Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. [Internet]. 2012 [cited 2014 Dec 11];18:268–281. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21793988. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. [Internet]. 2012 [cited 2014 Dec 11];18:268–281. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21793988.
11.
go back to reference Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley; 1989. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley; 1989.
14.
go back to reference Cetinkol Y, Yildirim AA, Telli M, Calgin MK. The investigation of oxacillinase/metallo-beta-lactamase genes and clonal analysis in carbapenem-resistant Klebsiella pneumoniae. Infez Med Italy. 2016;24:48–53. Cetinkol Y, Yildirim AA, Telli M, Calgin MK. The investigation of oxacillinase/metallo-beta-lactamase genes and clonal analysis in carbapenem-resistant Klebsiella pneumoniae. Infez Med Italy. 2016;24:48–53.
15.
go back to reference McDonnell MJ, Jary HR, Perry A, MacFarlane JG, Hester KLM, Small T, et al. Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med. [Internet]. 2015 [cited 2016 Feb 23];109:716–726. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25200914. McDonnell MJ, Jary HR, Perry A, MacFarlane JG, Hester KLM, Small T, et al. Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med. [Internet]. 2015 [cited 2016 Feb 23];109:716–726. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25200914.
16.
17.
go back to reference Izhakian S, Wasser WG, Fuks L, Vainshelboim B, Fox BD, Fruchter O, et al. Lobar distribution in non-cystic fibrosis bronchiectasis predicts bacteriologic pathogen treatment. Eur J Clin Microbiol Infect Dis. [Internet]. 2016 [cited 2016 Mar 13]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26873379. Izhakian S, Wasser WG, Fuks L, Vainshelboim B, Fox BD, Fruchter O, et al. Lobar distribution in non-cystic fibrosis bronchiectasis predicts bacteriologic pathogen treatment. Eur J Clin Microbiol Infect Dis. [Internet]. 2016 [cited 2016 Mar 13]; Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​26873379.
20.
go back to reference Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. [Internet]. 2013 [cited 2016 Jan 6];188:985–995. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23855620. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. [Internet]. 2013 [cited 2016 Jan 6];188:985–995. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23855620.
22.
go back to reference Calitri C, Scolfaro C, Colombo S, De Intinis G, Carraro F, Garazzino S, et al. Extended-Spectrum Beta Lactamase-producing Enterobacteriaceae among the pediatric population: who is at risk and why? Results from a single-centre prospective study. Infez Med Italy. 2016;24:318–25. Calitri C, Scolfaro C, Colombo S, De Intinis G, Carraro F, Garazzino S, et al. Extended-Spectrum Beta Lactamase-producing Enterobacteriaceae among the pediatric population: who is at risk and why? Results from a single-centre prospective study. Infez Med Italy. 2016;24:318–25.
23.
go back to reference Goeminne PC, Vandooren J, Moelants EA, Decraene A, Rabaey E, Pauwels A, et al. The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis. Respirology [Internet]. 2014 [cited 2015 Dec 28];19:203–210. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24286471. Goeminne PC, Vandooren J, Moelants EA, Decraene A, Rabaey E, Pauwels A, et al. The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis. Respirology [Internet]. 2014 [cited 2015 Dec 28];19:203–210. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​24286471.
25.
go back to reference Callejo-Torre F, Eiros Bouza JM, Olaechea Astigarraga P, Coma Del Corral MJ, Palomar Martinez M, Alvarez-Lerma F, et al. Risk factors for methicillin-resistant Staphylococcus aureus colonisation or infection in intensive care units and their reliability for predicting MRSA on ICU admission. Infez Med Italy. 2016;24:201–9. Callejo-Torre F, Eiros Bouza JM, Olaechea Astigarraga P, Coma Del Corral MJ, Palomar Martinez M, Alvarez-Lerma F, et al. Risk factors for methicillin-resistant Staphylococcus aureus colonisation or infection in intensive care units and their reliability for predicting MRSA on ICU admission. Infez Med Italy. 2016;24:201–9.
31.
go back to reference Lye DC, Earnest A, Ling ML, Lee T-E, Yong H-C, Fisher DA, et al. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect. [Internet]. 2012 [cited 2016 Feb 23];18:502–508. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21851482. Lye DC, Earnest A, Ling ML, Lee T-E, Yong H-C, Fisher DA, et al. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect. [Internet]. 2012 [cited 2016 Feb 23];18:502–508. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21851482.
32.
go back to reference Martin-Loeches I, Torres A, Rinaudo M, Terraneo S, de Rosa F, Ramirez P, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organi. J Infect. [Internet]. 2015 [cited 2016 Jan 8];70:213–222. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25445887. Martin-Loeches I, Torres A, Rinaudo M, Terraneo S, de Rosa F, Ramirez P, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organi. J Infect. [Internet]. 2015 [cited 2016 Jan 8];70:213–222. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25445887.
Metadata
Title
Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations
Authors
Rosario Menéndez
Raúl Méndez
Eva Polverino
Edmundo Rosales-Mayor
Isabel Amara-Elori
Soledad Reyes
José Miguel Sahuquillo-Arce
Laia Fernández-Barat
Victoria Alcaraz
Antoni Torres
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2754-5

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.